Skip to main content
. Author manuscript; available in PMC: 2020 Mar 12.
Published in final edited form as: Bioconjug Chem. 2018 Dec 26;30(1):63–69. doi: 10.1021/acs.bioconjchem.8b00720

Figure 4.

Figure 4.

dL5**-cetuximab facilitates trans-TEFLA with only one partner expressing transgenic FAP. (A) Schematic illustrating the trans-TEFLA principle applied to the dL5**-antibody system. (B) and (C) Co-cultured wild-type HaCaT and scFv1-expressing HEK-293 cells. HaCaTs are uniformly surface-labeled by dL5**-cetuximab bound to MG-PEG3500-TO1 dual fluorogen, with faint green fluorescence on the scFv1-HEKs. Bright fluorescence enhancement in both channels is observed at sites of intercellular contact (white arrows). (D) and (E) Equivalent cells incubated with single dyes (MG and TO1 fluorogens) exhibit similar labeling but without enhancement at contact sites. Green signal inside HaCaT cells represents background autofluorescence. Scale bars = 50μm.